期刊
CANCER CYTOPATHOLOGY
卷 128, 期 7, 页码 452-459出版社
WILEY
DOI: 10.1002/cncy.22300
关键词
indeterminate cytology; molecular diagnostics; personalized healthcare; thyroid cancer; thyroid nodule; variant detection
Recent analytical and clinical validation of the Afirma Xpression Atlas (XA) demonstrates test reliability and the identification of genomic alterations that may inform patient management. The updated Afirma Genomic Sequencing Classifier and XA reports aim to optimize the understanding of these contributions, including decisions about observation versus surgery, the need for disease-specific preoperative testing, associated neoplasm types, prognostics, the identification of molecular targets for systemic therapy, and the recognition of potential hereditary syndromes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据